These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 15015905)

  • 1. Dopamine partial agonists: a new class of antipsychotic.
    Lieberman JA
    CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole.
    McGavin JK; Goa KL
    CNS Drugs; 2002; 16(11):779-86; discussion 787-8. PubMed ID: 12383035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aripiprazole: a new atypical antipsychotic drug].
    Fischer B; Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole: a review of its use in the management of schizophrenia in adults.
    Croxtall JD
    CNS Drugs; 2012 Feb; 26(2):155-83. PubMed ID: 22296317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
    Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A
    Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
    de Oliveira IR; Elkis H; Gattaz WF; Chaves A; de Sena EP; de Matos E Souza FG; Campos JA; Bueno JR; E Silva JA; Louzã MR; de Abreu PB
    CNS Spectr; 2009 Feb; 14(2):93-102. PubMed ID: 19238124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aripiprazole use in children and adolescent psychiatric patients].
    Chevreuil C; Polard E; Lemonnier E; Guillemot P; Bentué-Ferrer D;
    Therapie; 2011; 66(2):123-30. PubMed ID: 21635859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical impact of aripiprazole in patients suffering from schizophrenia].
    Levoyer D; Drapier D; Fadier-Salicé G; Millet B
    Encephale; 2007; 33(3 Pt 1):332-8. PubMed ID: 17675931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist.
    Burke MJ; Lincoln J
    Ann Clin Psychiatry; 2006; 18(2):129-30. PubMed ID: 16754419
    [No Abstract]   [Full Text] [Related]  

  • 15. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
    Kerpel-Fronius S; Lóránt M
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):177-84. PubMed ID: 15825673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
    DeLeon A; Patel NC; Crismon ML
    Clin Ther; 2004 May; 26(5):649-66. PubMed ID: 15220010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.